share_log

Neurocrine Biosciences Raises FY24 Net Product (Valbenazine) Revenue Outlook To $2.30B-$2.32B

Benzinga ·  Oct 30 19:07
Neurocrine Biosciences Raises FY24 Net Product (Valbenazine) Revenue Outlook To $2.30B-$2.32B
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment